The Food and Drug Administration recently extended to 30 months the shelf life for certain lots of Gohibic (vilobelimab), authorized for emergency use to treat COVID-19 in certain hospitalized adults. The six-month extension applies to all retained product held in accordance with storage conditions detailed in the fact sheet for health care providers

Related News Articles

Headline
The Pfizer and Moderna COVID-19 vaccines can cause myocarditis, but do not appear to cause infertility, Guillain-Barré syndrome, Bell’s palsy, thrombosis with…
Headline
The Food and Drug Administration recently granted emergency use authorization for the first over-the-counter home antigen test to detect both flu and COVID-19…
Headline
Centers for Disease Control and Prevention Director Mandy Cohen, M.D., Feb. 28 endorsed a recommendation by its Advisory Committee on Immunization Practices…
Headline
Paxlovid may no longer be distributed with an emergency use label after March 8, the Food and Drug Administration announced. Providers may dispense unexpired…
Headline
A CDC study  released Dec. 21 found low COVID-19 and flu vaccination coverage for most adults, and low RSV vaccination coverage for adults aged 60 and…
Headline
The Home Test to Treat program now offers free testing, telehealth and treatment for both COVID-19 and flu to eligible adults nationwide, the National…